|
市場調查報告書
癌症治療之分子診斷用產品及技術趨勢
An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology "
|
癌症治療之分子診斷用產品及技術趨勢 是由出版商HBS Consulting在2006年05月所出版的。
這份英文市場調查報告書價格從美金5500起跳。
提供醫療儀器、醫藥品、生物科技相關、新商業等市場趨勢之調查分析資訊的 HBS Consulting (總公司:倫敦),針對癌症治療之分子診斷用產品及技術趨勢進行調查分析,並出版報告書 "An Evaluation of Products and Technologies for Molecular Diagnostics within Oncology"。
本報告書內容包括:法國、德國、義大利、英國、美國的癌症治療之分子診斷學市場簡介與市場成長主要因素、技術趨勢、國家別法規趨勢,以及未來發展趨勢與新興技術等。內容綱要摘記如下:
序章
第1章 法國
- 現況
- 受訪者
- 核酸基礎的實驗
- 遺傳基因實驗
- HPV 實驗
- 癌症治療市場
- 核酸樣本準備
- 利用核酸( DNA )診斷癌症的趨勢
- NAT:適用與技術認可
- 製作與償付
- 摘要與結論
第2章 德國
- 現況
- 受訪者
- 核酸基礎的實驗
- 遺傳基因實驗
- HPV 實驗
- 癌症治療市場
- 核酸樣本準備
- 利用核酸( DNA )診斷癌症的趨勢
- NAT:適用與技術認可
- 製作與償付
- 摘要與結論
第3章 義大利
- 現況
- 受訪者
- 核酸基礎的實驗
- 遺傳基因實驗
- HPV 實驗
- 癌症治療市場
- 核酸樣本準備
- 利用核酸( DNA )診斷癌症的趨勢
- NAT:適用與技術認可
- 製作與償付
- 摘要與結論
第4章 英國
- 現況
- 受訪者
- 核酸基礎的實驗
- 遺傳基因實驗
- HPV 實驗
- 癌症治療市場
- 核酸樣本準備
- 利用核酸( DNA )診斷癌症的趨勢
- NAT:適用與技術認可
- 製作與償付
- 摘要與結論
第5章 美國
- 現況
- 受訪者
- 核酸基礎的實驗
- 遺傳基因實驗
- HPV 實驗
- 癌症治療市場
- 核酸樣本準備
- 利用核酸( DNA )診斷癌症的趨勢
- NAT:適用與技術認可
- 製作與償付
- 摘要與結論
Abstract
This latest Multi Client Publication from HBS Consulting provides:
- An overview of current industry-landscape for molecular diagnostics within
the oncology area
- Analysis of the key European markets including forecasts for growth,
drivers and restraints in the marketplace
- Reimbursement and legislation environment, the most relevant national
guidelines relating to genetic testing
- Understanding of market opportunities for molecular diagnostics within the
oncology market as an area of growth, research and future developments
Overview
Project Objectives
The primary objective of this report, compiled from an analysis of primary and
secondary research data, is to provide an overview of the molecular
diagnostics market for selected oncology markers in the country markets listed
below.
- France
- Germany
- Italy
- United Kingdom
- USA
The following key issues have been addressed:
- Provide a reflective picture of the type and number of relevant testing
institutions
- Which and how many parameters are tested (market size). Top 3 solid
markers, top 3 lymphoid markers and emerging markers identified.
- Which assays are used (home brew or commercial)
- Current market growth per parameter
- Expected market growth rates per parameter in the next 5 years
- Which technologies are used (PCR, RT-PCR, FISH, sequencing, microarrays,
others) and what is the anticipated shift in use of these.
- Devices used
- The regulatory issues per country (legislation, reimbursement etc.)
- Future trends & emerging technologies
Table of Contents
Introduction
Part 1 - France
- Current Situation
- Respondent Population France
- Nucleic Acid Based Testing
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumour Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Markers
- CE approval
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 2 - Germany
- Current Situation
- Respondent Population Germany
- Nucleic Acid Based Testing
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in Genetics Based Oncology Diagnostics
- Emerging Markers
- CE certification
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 3 - Italy
- Current Situation
- Respondent Population - Italy
- Nucleic Acid Based Testing
- Types of testing performed
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Markers
- CE or FDA approval
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 4 - United Kingdom
- Current Situation
- Respondent Population UK
- Nucleic Acid Based Testing
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Markers
- CE certification
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
Part 5 - USA
- Current Situation
- Respondent Population US
- Nucleic Acid Based Testing
- Types of testing performed
- Genetic Testing - Routine or Research
- HPV Testing
- Oncology Markers
- Solid Tumor Marker
- Lymphoid Tumor Marker
- Nucleic Acid Sample Preparation
- Trends in NA-Based Oncology Diagnostics
- Emerging Marker
- Test Certification
- NAT - application and technical appraisal
- Politics and Reimbursement
- Drivers of NAT
- Restraints on NAT
- Summary and Conclusions
|